Intravenous cidofovir-induced resolution of disfiguring cutaneous human papillomavirus infection

Journal of the American Academy of Dermatology

Volumn 55, Issue 3, 2006, Pages 533-536

  Kottke, Margaret D ^a   Parker, Sareeta R S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; AZITHROMYCIN; CIDOFOVIR; COTRIMOXAZOLE; EFAVIRENZ; FLUOROURACIL; IMIQUIMOD; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PROBENECID; SALICYLIC ACID; SAQUINAVIR; ZIDOVUDINE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CRYOTHERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; LABORATORY TEST; MALE; PRIORITY JOURNAL; PROTEINURIA; SKIN INFECTION; TREATMENT RESPONSE; VERRUCA VULGARIS; VIRUS INFECTION; WART VIRUS;

ADULT; ANTIVIRAL AGENTS; CYTOSINE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PAPILLOMAVIRUS INFECTIONS; PHOSPHONIC ACIDS; SKIN DISEASES, VIRAL; TREATMENT OUTCOME;

EID: 33746934192     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.01.007     Document Type: Article

References (37)

1. Horn T.D., Johnson S., Helm R.M., and Roberson P. Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens. Arch Dermatol 141 (2005) 589-594
2. Williams H.C., Pottier A., and Strachan D. The descriptive epidemiology of warts in British schoolchildren. Br J Dermatol 128 (1993) 504-511
3. Larsson P.A., and Liden S. Prevalence of skin diseases among adolescents 12-16 years of age. Acta Derm Venereol 60 (1980) 415-423
4. Baken L.A., Koutsky L.A., Kuypers J., Kosorok M.R., Lee S.K., Kiviat N.B., et al. Genital human papillomavirus infection among male and female sex partners: prevalence and type-specific concordance. J Infect Dis 171 (1995) 429-432
5. Bauer H.M., Ting Y., Greer C.E., Chambers J.C., Tashiro C.J., Chimera J., et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 265 (1991) 472-477
6. Baldwin S.B., Wallace D.R., Papenfuss M.R., Abrahamsen M., Vaught L.C., and Kornegay J.R. Human papillomavirus infection in men attending a sexually transmitted disease clinic. J Infect Dis 187 (2003) 1064-1070
7. Lazcano-Ponce E., Herrero R., Munoz N., Hernandez-Avila M., Salmeron J., Levya A., et al. High prevalence of human papillomavirus infection in Mexican males. Sex Transm Dis 28 (2001) 277-280
8. Sawchuk W.S., Weber P.J., Lowy D.R., and Dzubow L.M. Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: detection and protection. J Am Acad Dermatol 21 (1989) 41-49
9. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
10. Stoler M.H., and Broker T.R. In situ hybridization detection of human papillomavirus DNAs and messenger RNAs in genital condylomas and cervical carcinoma. Hum Pathol 17 (1986) 1250-1258
11. Koutsky L.A., Holmes K.K., Critchlow C.W., Stevens C.E., Paavonen J., Beckmann A.M., et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 327 (1992) 1272-1278
12. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 (2002) 1645-1651
13. Dillner J., von Krogh G., Horenblas S., and Meijer C.J. Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl 205 (2000) 189-193
14. Bonez W., and Reichman R.C. Papillomaviruses. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th ed. (2005), Elsevier, Philadelphia 1841-1856
15. Lutzner M.A., Orth G., Dutronquav V., Ducasse M.F., Kreis H., and Crosnier J. Detection of human papillomavirus type 5 DNA in skin cancers of an immunosuppressed renal allograft recipient. Lancet 2 (1983) 422-424
16. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., and Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 (1990) 1129-1136
17. Chopra K.F., and Tyring S.K. The impact of the human immunodeficiency virus on the human papillomavirus epidemic. Arch Dermatol 133 (1997) 629-633
18. Bernard C., Mougin C., Madoz L., Drobacheff C., Van Landuyt H., Laurent R., et al. Viral co-infections in human papillomavirus-associated anogenital lesions according to the serostatus for the human immunodeficiency virus. Int J Cancer 52 (1992) 731-737
19. Garzetti G.G., Ciavattini A., Butini L., Vecchi A., and Montroni M. Cervical dysplasia in HIV-seropositive women: role of human papillomavirus infection and immune status. Gynecol Obstet Invest 40 (1995) 52-56
20. Steinberg B.M., Gallagher T., Stoler M., and Abramson A.L. Persistence and expression of human papillomavirus during interferon therapy. Arch Otolaryngol Head Neck Surg 114 (1988) 27-32
21. Ferenczy A., Mitao M., Nagai N., Silverstein S.J., and Crum C.P. Latent papillomavirus and recurring genital warts. N Engl J Med 313 (1985) 784-788
22. Plosker G.L., and Noble S. Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS. Drugs 58 (1999) 325-345
23. Cundy K.C. Clinical pharmacokinetics if the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 36 (1999) 127-143
24. Husak R., Zouboulis C.C., Sander-Bahr C., Hummel M., and Orfanos C.E. Refractory human papillomavirus-associated oral warts treated topically with 1-3% cidofovir solutions in human immunodeficiency virus type 1-infected patients. Br J Dermatol 152 (2005) 590-591
25. Tobin A.M., Cotter M., Irvine A.D., and Kirby B. Successful treatment of a refractory verruca in a child with acute lymphoblastic leukaemia with topical cidofovir. Br J Dermatol 152 (2005) 386-388
26. Snoek R., Bossens M., Parent D., Delaere B., Degreef H., Van Ranst M., et al. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis 33 (2001) 597-602
27. Matteelli A., Beltrame A., Graifemberghi S., Forleo M.A., Gulletta M., Ciravolo G., et al. Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons. Sex Transm Dis 28 (2001) 343-346
28. Meadows K.P., Tyring S.K., Pavia A.T., and Rallis T.M. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol 133 (1997) 987-990
29. Lalezari J., Schaker T., and Feinberg J. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 176 (1997) 892-898
30. Snoek R., Van Laethem Y., De Clercq E., De Maubeuge J., and Clumeck N. Treatment of a bowenoid papulosis of the penis with local applications of cidofovir in a patient with acquired immunodeficiency syndrome. Arch Intern Med 161 (2001) 2382-2384
31. Snoek R., Wellens W., Desloovere C., Van Ranst M., Naesens L., De Clercq E., et al. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine]. J Med Virol 54 (1998) 219-225
32. Lee A.S., and Rosen C.A. Efficacy of cidofovir injection for the treatment of recurrent respiratory papillomatosis. J Voice 18 (2004) 551-556
33. Mandell D.L., Arjmand E.M., Kay D.J., Casselbrant M.L., and Rosen C.A. Intralesional cidofovir for pediatric recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 130 (2004) 1319-1323
34. Hivnor C., Shepard J.W., Shapiro M.S., and Vittorio C.C. Intravenous cidofovir for recalcitrant verruca vulgaris in the setting of HIV. Arch Dermatol 140 (2004) 13-14
35. Lalezari J.P., Holland G.N., Kramer F., McKinley G.F., Kemper C.A., Ives D.V., et al. Randomized controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 17 (1998) 339-344
36. Ortiz A., Justo P., Sanz A., Melero R., Caramelo C., Guerrero M.F., et al. Tubular cell apoptosis and cidofovir-induced acute renal failure. Antivir Ther 10 (2005) 185-190
37. Lacy S.A., Hitchcock M.J., Lee W.A., Tellier P., and Kundy K.C. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol Sci 44 (1998) 97-106